KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Cardlytics (CDLX) EBIT Margin (2017 - 2025)

Cardlytics (CDLX) has disclosed EBIT Margin for 9 consecutive years, with 10.86% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBIT Margin rose 37.0% year-over-year to 10.86%, compared with a TTM value of 43.65% through Dec 2025, up 2660.0%, and an annual FY2025 reading of 43.65%, up 2660.0% over the prior year.
  • EBIT Margin was 10.86% for Q4 2025 at Cardlytics, up from 132.33% in the prior quarter.
  • Across five years, EBIT Margin topped out at 52.49% in Q1 2022 and bottomed at 463.78% in Q4 2022.
  • Average EBIT Margin over 5 years is 69.18%, with a median of 28.93% recorded in 2023.
  • The sharpest move saw EBIT Margin plummeted -44556bps in 2022, then skyrocketed 34836bps in 2023.
  • Year by year, EBIT Margin stood at 18.22% in 2021, then plummeted by -2445bps to 463.78% in 2022, then soared by 75bps to 115.43% in 2023, then soared by 90bps to 11.24% in 2024, then grew by 3bps to 10.86% in 2025.
  • Business Quant data shows EBIT Margin for CDLX at 10.86% in Q4 2025, 132.33% in Q3 2025, and 20.22% in Q2 2025.